
Cassandra M Berry

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7548419/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Antibody immunoprophylaxis and immunotherapy for influenza virus infection: Utilization of monoclonal or polyclonal antibodies?. Human Vaccines and Immunotherapeutics, 2018, 14, 796-799.	1.4	15
2	A Technique for Inspiring Scientific Inquiry Using a Creative Scenario. American Biology Teacher, 2017, 79, 671-677.	0.1	2
3	Plasma CXCL10, sCD163 and sCD14 Levels Have Distinct Associations with Antiretroviral Treatment and Cardiovascular Disease Risk Factors. PLoS ONE, 2016, 11, e0158169.	1.1	28
4	Understanding Interferon Subtype Therapy for Viral Infections: Harnessing the Power of the Innate Immune System Cytokine and Growth Factor Reviews, 2016, 31, 83-90.	3.2	16
5	Towards a Universal Influenza Virus Vaccine Eliciting Broadly Neutralising Haemagglutinin Antibodies. Journal of Vaccines & Vaccination, 2015, 06, .	0.3	2
6	Modulation of Innate Immune Responses by Influenza-Specific Ovine Polyclonal Antibodies Used for Prophylaxis. PLoS ONE, 2014, 9, e89674.	1.1	11
7	Persistent and Compartmentalised Disruption of Dendritic Cell Subpopulations in the Lung following Influenza A Virus Infection. PLoS ONE, 2014, 9, e111520.	1.1	15
8	Elevated Plasma Soluble CD14 and Skewed CD16+ Monocyte Distribution Persist despite Normalisation of Soluble CD163 and CXCL10 by Effective HIV Therapy: A Changing Paradigm for Routine HIV Laboratory Monitoring?. PLoS ONE, 2014, 9, e115226.	1.1	34
9	Interferonâ€alpha, immune activation and immune dysfunction in treated HIV infection. Clinical and Translational Immunology, 2014, 3, e10.	1.7	59
10	Passive Broad-Spectrum Influenza Immunoprophylaxis. Influenza Research and Treatment, 2014, 2014, 1-9.	1.5	4
11	Engineering a Biocompatible Scaffold with Either Micrometre or Nanometre Scale Surface Topography for Promoting Protein Adsorption and Cellular Response. International Journal of Biomaterials, 2013, 2013, 1-16.	1.1	68
12	Interferons as biomarkers and effectors: lessons learned from animal models. Biomarkers in Medicine, 2012, 6, 159-176.	0.6	10
13	Improved vaccine protection against retrovirus infection after co-administration of adenoviral vectors encoding viral antigens and type I interferon subtypes. Retrovirology, 2011, 8, 75.	0.9	20